Search Within

Hematologic Malignancies, Division of

Formats
  1. Meeting Abstract (6188)
  2. Journal Article (5670)
  3. Review (401)
  4. Book Section (186)
  5. Editorial (182)
  6. Research Letter (167)
  7. Guidelines (84)
  8. Conference Paper (65)
  9. Correspondence (56)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Department of Medicine (12945)
  2. Center for Hematologic Malignancies (10353)
  3. GSK Faculty (4407)
  4. Adult Leukemia (3562)
  5. Bone Marrow Transplant (2763)
  6. Lymphoma (2632)

More Groups

People
  1. Sergio Giralt (1047)
  2. Miguel-Angel Perales (908)
  3. Ross Levine (769)
  4. Andrew Zelenetz (765)
  5. Martin Tallman (649)
  6. Steven Horwitz (644)

More People

Years
  1. 2025 (158)
  2. 2024 (653)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3352)
  2. Journal of Clinical Oncology (1208)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (327)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (237)

More Publications

Publishers
  1. American Society of Hematology (3617)
  2. Elsevier Inc. (1605)
  3. American Society of Clinical Oncology (1259)
  4. Nature Publishing Group (985)
  5. American Association for Cancer Research (632)
  6. Wiley Blackwell (430)

More Publishers

Results (13025)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM)
    Meeting Abstract

    Lesokhin, A. M.; Arnulf, B.; Niesvizky, R.; Mohty, M.; Bahlis, N. J.; Tomasson, M. H.; Rodríguez-Otero, P.; Quach, H.; Raje, N. S.; Iida, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity
    Meeting Abstract

    Locke, F. L.; Siddiqi, T.; Jacobson, C. A.; Ghobadi, A.; Ahmed, S.; Miklos, D. B.; Perales, M. A.; Munoz, J.; Logan, B.; Hu, Z. H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Biomarkers of response to neoadjuvant atezolizumab with gemcitabine and cisplatin in muscle-invasive bladder cancer
    Meeting Abstract

    Lattanzi, M.; Solovyov, A.; Lihm, J.; Quinlan, C.; Whiting, K.; Li, H.; Al-Ahmadie, H. A.; Teo, M. Y.; Aggen, D. H.; Ostrovnaya, I.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)
    Meeting Abstract

    Kyi, C.; Rubinstein, M. M.; Shah, P.; Zhou, Q.; Iasonos, A.; Liu, Y.; Ramirez, L.; Paroder, V.; Green, A.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Myeloma developing regimens using genomics (MyDRUG) trial: Results from the RAS mutation targeting arm
    Meeting Abstract

    Kumar, S.; Bianchi, G.; Biran, N.; Hultcrantz, M.; Richter, J. R.; Vij, R.; Ye, J. C.; Zonder, J. A.; DiLello, L.; Yesil, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access
    Meeting Abstract

    Kourelis, T.; Bansal, R.; Patel, K. K.; Berdeja, J. G.; Raje, N. S.; Alsina, M.; Cohen, A. D.; Siegel, D. S. D.; Mailankody, S.; Htut, M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Quality-adjusted time without symptoms or toxicities (Q-TWiST) analysis of ZUMA-7, a randomized controlled trial of axicabtagene ciloleucel versus standard of care for second-line large B-cell lymphoma
    Meeting Abstract

    Kersten, M. J.; Qiao, Y.; Shah, R.; Solem, C.; Snider, J.; To, C. A.; Cheng, P.; Spooner, C.; Perales, M. A.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A robust, trial-agnostic gene signature for response to tyrosine kinase inhibition in ccRRCC
    Meeting Abstract

    Khaleel, S. S.; Liu, M.; Kuo, F.; Kotecha, R.; Lee, C. H.; Voss, M. H.; Motzer, R. J.; Hakimi, A. A.; Reznik, E.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies
    Meeting Abstract

    Joffe, E.; Nowakowski, G. S.; Tun, H. W.; Rosenthal, A. C.; Lunning, M. A.; Ramchandren, R.; Li, C. C.; Zhou, L.; Martinez, E.; Von Roemeling, R. W.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers
    Meeting Abstract

    Johnson, M. L.; Dy, G. K.; Mamdani, H.; Dowlati, A.; Schoenfeld, A. J.; Pacheco, J. M.; Sanborn, R. E.; Menon, S. P.; Santiago, L.; Yaron, Y.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save